GLP-1 receptor agonists (mainstream type): Focus on "appetite control + blood glucose regulation", covering all the above 3 basic mechanisms, with mild fat loss and high safety.
Other niche weight-loss peptides: Some target and inhibit fat synthesis (reduce adipocyte neogenesis) or accelerate energy consumption, with core logic still adhering to "physiology-aligned and precise targeting".
